1-3 of 3
Timothy Z. Lehmberg, BA
Close
Sort by
Journal Articles

Dynamic BH3 Profiling Predicts Patient Response and MRD Status in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Frontline Treatment with Kinase Inhibitor Plus FCR (KI+FCR)

Timothy Z. Lehmberg, BA, Rebecca Valentin, MD, Stacey M. Fernandes, BS, Jennifer R. Brown, MD PhD, Matthew S Davids
Journal: Blood
Blood (2018) 132 (Supplement 1): 4395.
https://doi.org/10.1182/blood-2018-99-115151
Published: 2018
Journal Articles

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Rebecca Valentin, MD, Marisa O. Peluso, MS, Timothy Z. Lehmberg, BA, Ammar Adam, DVM, Li Zhang, MA, Caroline M. Armet, BS, Jennifer L. Guerriero, PhD, Benjamin H. Lee, MD PhD, Vito J. Palombella, PhD, Pamela M. Holland, PhD, Alison M. Paterson, PhD, Matthew S. Davids, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4393.
https://doi.org/10.1182/blood-2018-99-110181
Published: 2018
Journal Articles

Dynamic BH3 Profiling to Assess the Effects of Novel Agents on Anti-Apoptotic Protein Dependence of CLL Cells

Rebecca Valentin, MD, Jing Deng, PhD, Elisa Ten Hacken, PhD, Timothy Z. Lehmberg, BA, Silvia Buonamici, PhD, Donna S. Neuberg, ScD, Catherine J. Wu, MD, Anthony Letai, MD PhD, Matthew S. Davids, MD MMSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 4289.
https://doi.org/10.1182/blood.V130.Suppl_1.4289.4289
Published: 2017